Neogenomics Inc
SWB:NG9
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of 
Neogenomics Inc (NG9) under the Base Case is EUR per share.
Compared with the current market price of 14.945 EUR, the stock appears .
The intrinsic value is the average of valuations using the DCF method and multiples.
Do our valuations actually work? See backtest results .
What one share is worth in the bear, base and bull cases.
Create a free account · No card needed
Do our valuations actually work? See backtest results .
Intrinsic value next to the price over the past 5 years, and what happened after valuations like today’s.
Create a free account · No card needed
Fundamental Analysis
What Neogenomics Does
Neogenomics is a specialty laboratory company focused on cancer testing. It runs tests on tissue, blood, and bone marrow to help doctors diagnose cancer, classify tumors, and choose treatments. Its main customers are oncologists, hospitals, pathology groups, and other medical providers that need detailed cancer lab results.
- Headquarters
- United States of America US
- Employees
- 2 500
- IPO date
- Dec 10, 2012
Neogenomics has no economic moat
Neogenomics Inc lacks an economic moat, leaving it vulnerable to competitive pressures and market challenges.
Read the full moat analysis
Revenue & Expenses Breakdown
Neogenomics Inc
Earnings Waterfall
Neogenomics Inc
What is the Intrinsic Value of one NG9 stock?
The intrinsic value for Neogenomics Inc (NG9) under the Base Case is EUR.
Is NG9 stock undervalued or overvalued?
Compared with the current market price of 14.945 EUR, the stock appears .
